Harmony Biosciences Holdings - Asset Resilience Ratio
Harmony Biosciences Holdings (HRMY) has an Asset Resilience Ratio of 4.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Harmony Biosciences Holdings's Asset Resilience Ratio has changed over time. Check Harmony Biosciences Holdings (HRMY) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Harmony Biosciences Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Harmony Biosciences Holdings.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $51.52 Million | 4.05% |
| Total Liquid Assets | $51.52 Million | 4.05% |
Asset Resilience Insights
- Limited Liquidity: Harmony Biosciences Holdings maintains only 4.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Harmony Biosciences Holdings Industry Peers by Asset Resilience Ratio
Compare Harmony Biosciences Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Harmony Biosciences Holdings (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Harmony Biosciences Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.80% | $22.84 Million | $1.27 Billion | +0.38pp |
| 2024-12-31 | 1.42% | $14.19 Million | $999.20 Million | -3.73pp |
| 2023-12-31 | 5.15% | $41.80 Million | $811.45 Million | -6.62pp |
| 2022-12-31 | 11.77% | $79.33 Million | $673.87 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $433.44 Million | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more